Drug intelligence / Profile preview

karanjin

Development stage
Preclinical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Topical
01

Overview

Karanjin is a naturally occurring furanoflavonol, a type of benzofuran flavonoid, primarily isolated from the seeds of the karanja tree (Millettia pinnata, also called Pongamia glabra)[1][2][3][8][9]. It is used mainly as a bioinsecticide and acaricide in agriculture, but also studied for multiple biological activities, including antioxidant, anti-inflammatory, anti-ulcerogenic, antimicrobial, hypoglycemic, antidiabetic, and anticancer properties[1][2][4][5]. Pharmacological studies report its effects as a H+, K+-ATPase inhibitor (anti-ulcer activity), lipoxygenase inhibitor (anti-inflammatory activity), GLUT4 translocation stimulator (potential anti-diabetic action), and promoter of cancer cell apoptosis[1][2][4][5]. The compound is recognized in traditional Indian medicine, including Ayurveda and Siddha systems, for a range of ailments such as bronchitis, fever, arthritis, skin diseases, and gastrointestinal disorders, though it has not been developed as a pharmaceutical drug and does not have regulated medical indications[1][2][7].

Other names
3-methoxy-2-phenylfuro[2,3-h]chromen-4-one3-Methoxy-2-phenyl-4H-furo[2,3-h]-1-benzopyran-4-one3-Methoxy-2-phenyl-4H-furo(2,3-h)[1]benzopyran-4-oneKaranjin-RMKARNJINNSC254030NSC-254030NSC 254030NSC 335755NSC335755NSC-335755KranjinCysteinic acid
02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)ATP4A (Potassium–transporting ATPase alpha chain 1)OLR1 (Lectin-like oxidized LDL receptor-1)ALOX5 (Arachidonate 5-lipoxygenase)

Beyond the preview

Go deeper on karanjin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on karanjin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call